Contact information
Colleges
Oliver Rider
BA (hons), BMBCh (hons), FRCP (UK), DPhil (Oxon)
Professor of Cardiovascular Medicine
- British Heart Foundation Senior Clinical Research Fellow
- Deputy Clinical Director of OCMR
- Honorary Consultant Cardiologist
After studying medicine at Pembroke College (1996-2002) I completed the Royal College Examinations and specialized in Cardiology. In 2005 I was awarded a Wellcome Trust Junior Research Fellowship to complete my DPhil in Cardiovascular medicine at Oxford, where I used advanced cardiac magnetic resonance imaging and spectroscopy to study the effects of obesity and weight loss on myocardial metabolism and function. For this work I was awarded the American Heart Association Young Investigator Award for Nutrition Physical Activity and Metabolism (2008) and took up the role of Clinical Lecturer in Cardiovascular Medicine in Oxford in 2010 where I furthered my research into obesity. In 2015 I was appointed as an Honorary Consultant Cardiologist and Deputy Clinical Director or the University of Oxford Centre for Clinical Magnetic Resonance Research. I held a British Heart Foundation Intermediate Clinical Research Fellowship between 2016 and 2022 and was awarded the BHF/BCS Michael Davies Early Career Award in 2019, and followed this with a British Heart Foundation Senior Clinical Research Fellowship award in 2022. I now run a research group that uses advanced cardiac magnetic resonance imaging and spectroscopy to investigate the relationship between cardiac substrate metabolism, cardiac energetics and cardiac function in multiple diseases with a focus on cardiometabolic heart disease and heart failure.
Recent publications
-
Myocardial Strain Imaging: Theory, Current Practice, and the Future.
Journal article
Smiseth OA. et al, (2024), JACC Cardiovasc Imaging
-
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes
Journal article
Chowdhary A. et al, (2024), Journal of the American College of Cardiology, 84, 540 - 557
-
The effect of sodium-glucose co-transporter 2 inhibitors on outcomes after cardiac resynchronization therapy.
Journal article
Bray JJH. et al, (2024), ESC Heart Fail
-
The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
Journal article
Buttice L. et al, (2024), Diabetes Obes Metab
-
Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction.
Journal article
Henry JA. et al, (2024), J Clin Med, 13